Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: A long‐term follow‐up study
- 9 April 2022
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 29 (6) , 412-419
Abstract
The long‐term impact, incidence and risk factors of thyroid dysfunction in chronic hepatitis B (CHB) patients receiving pegylated interferon (IFN) alpha (PegIFN‐alpha) therapy remain unclear. We aim to investigate the long‐term safety of thyroid dysfunction in CHB patients receiving PegIFN‐alpha. A retrospective observational study of 425 CHB patients with normal baseline thyroid function was carried out. Patients were followed up over 10 years to assess thyroid function after receiving IFN. At the end of the IFN therapy, 67 patients (15.8%) had developed thyroid dysfunction, 31 patients (46.3%) had hyperthyroidism and 64.4% presented with subclinical thyroid dysfunction. In follow‐up of thyroid dysfunction patients, 37 patients (74.0%) spontaneously regained normal thyroid function. Pretreatment thyroid‐stimulating hormone (TSH) level, thyroid peroxidase antibody (TPOAb) positivity and free thyroxine (FT4) were independent risk factors associated with thyroid dysfunction incidence. High TSH level (OR = 9.866, 95%CI, 3.245–29.998) was associated with a greater likelihood of hypothyroidism. High FT4 levels (OR = 0.464, 95%CI, 0.248–0.868) indicate a low likelihood of thyroid dysfunction. Thyroid dysfunction is a common but acceptable side effect of IFN therapy for CHB. Most thyroid dysfunction is reversible. Pretreatment TSH level and TPOAb positivity are risk factors for thyroid dysfunction development during IFN therapy. A high TSH level predicts an increased incidence of hypothyroidism. Moreover, FT4 may be a protective factor for thyroid dysfunction.Keywords
Funding Information
- National Natural Science Foundation of China (81670528, 81672009, 81800526, 81800529, 81871640)
This publication has 14 references indexed in Scilit:
- Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)Journal of Hepatology, 2014
- Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNAScience, 2014
- Thyroid dysfunction in a UK hepatitis C population treated with interferon‐α and ribavirin combination therapyClinical Endocrinology, 2010
- Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2aGastroenterology, 2009
- Interferon Therapy for Chronic Hepatitis BClinics in Liver Disease, 2007
- Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinomaJournal of Hepatology, 2007
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2005
- Type I Interferons Modulate the Expression of Thyroid Peroxidase, Sodium/Iodide Symporter, and Thyroglobulin Genes in Primary Human Thyrocyte CulturesThe Journal of Clinical Endocrinology & Metabolism, 2005
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- Interferon-α and Autoimmune Thyroid DiseaseThyroid®, 2003